The choice of antiepileptic drugs in newly diagnosed epilepsy: A national French survey

Epileptic Disorders

Volumn 6, Issue 4, 2004, Pages 255-265

  Semah, Franck ^a,b   Picot, Marie Christine ^c   Derambure, Philippe ^d   Dupont, Sophie ^e   Vercueil, Laurent ^f   Chassagnon, Serge ^g   Marchal, Cécile ^h   Thomas, Pierre ⁱ   Ryvlin, Philippe ^j  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b DIF   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d Clinical Neurophysiology Department   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Neurology Department   (France)

^g HÔPITAL CIVIL   (France)

^h HÔPITAL PELLEGRIN   (France)

ⁱ PASTEUR HOSPITAL   (France)

^j HÔPITAL NEUROLOGIQUE   (France)

more..

Author keywords

Antiepileptic drugs; Epilepsy; Guidelines; Monotherapy; Survey; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABSENCE; ADULT; ADULT DISEASE; AGE; AGING; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CRYPTOGENIC FOCAL EPILEPSY; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; EPILEPSY; FOCAL EPILEPSY; FRANCE; GENDER; GENERALIZED EPILEPSY; HEALTH SURVEY; HUMAN; IDIOPATHIC DISEASE; MONOTHERAPY; MYOCLONUS EPILEPSY; NEWLY DIAGNOSED EPILEPSY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT FAILURE; UNCLASSIFIED EPILEPSY; UNDETERMINED IDIOPATHIC GENERALIZED EPILEPSY;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHOICE BEHAVIOR; CONSENSUS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; EPILEPSY; FEMALE; FRANCE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; SYNDROME; TREATMENT FAILURE;

EID: 11844278405     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chadwick DW, Anhut H, Creiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Cabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282-8.
2. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
3. Brodie MJ, Richens A, Yuen AWC, The UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9.
4. Kälviäinen R, Äikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52: 989-96.
5. Lindberger M, Alenius M, Prisen L, et al. Cabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia 2000; 41: 1289-95.
6. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-74.
7. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73.
8. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60.
9. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-75.
10. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-90.
11. Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia 1999; 40(Suppl 6): S17-S22.
12. Marson AG, Chadwick DW. New drug treatments for epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 143-7.
13. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia 2003; 44(Suppl 4): 3-10.
14. Karceski S, Morrell MJ, Carpenter D. Treatment of Epilepsy. Epilepsy Behav 2001; 2: A1-A50.
15. Kahn DA, Docherty JP, Carpenter D, Frances A. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull 1997; 33: 631-9.
16. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
17. Cook DJ, Greengold NL, Ellrodt AC, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997; 127: 210-6.
18. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-9.
19. Samren EB, Van Duijn CM, Christiaens CC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-46.
20. Tennis P, Eldridge RR. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161-7.
21. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord 2003; 5: 125-32.
22. Shorvon SD, Chadwick DW, Galbraith AW, Reynolds EH. One Drug for epilepsy. BMJ 1978; 1: 474-6.